Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
about
Harnessing the apoptotic programs in cancer stem-like cellsAclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiationRegulation of Mcl-1 by SRSF1 and SRSF5 in cancer cellsSuppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitorsCM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemiaBcr/Abl interferes with the Fanconi anemia/BRCA pathway: implications in the chromosomal instability of chronic myeloid leukemia cells.Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosisSAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.Investigation into omacetaxine solution stability for in vitro study.The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1.Serine 162, an essential residue for the mitochondrial localization, stability and anti-apoptotic function of Mcl-1.The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737Imatinib spells BAD news for Bcr/abl-positive leukemiasA critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells.Human cytomegalovirus activation of ERK and myeloid cell leukemia-1 protein correlates with survival of latently infected cells.Rapid turnover of mcl-1 couples translation to cell survival and apoptosis.MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis.Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cellsGILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemiaPotentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML.MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.Evolving molecular therapy for chronic myeloid leukaemia--are we on target?Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactionsFoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesisSynergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.Myeloid cell leukemia-1 as a therapeutic target.Human Cytomegalovirus Promotes Survival of Infected Monocytes via a Distinct Temporal Regulation of Cellular Bcl-2 Family Proteins.Fangchinoline induces G0/G1 arrest by modulating the expression of CDKN1A and CCND2 in K562 human chronic myelogenous leukemia cells.Downregulation of Mcl-1 through inhibition of translation contributes to benzyl isothiocyanate-induced cell cycle arrest and apoptosis in human leukemia cells.Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in miceBcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target.
P2860
Q26801037-99B98D83-EF77-4E2C-A63A-31000BDBA822Q28397002-CE6AFB09-A75E-4C22-92D8-02325404CE14Q28484403-51FD7093-376F-4208-AF1B-0FE96EE561C5Q33259095-C95D5036-432D-4BBD-9F91-7978D4DC9FA6Q33418324-71A643A0-C6AD-458D-8482-C10B79C90725Q33728096-D6A17F33-FC08-4C36-A0C1-4DDBCE6024ADQ33784347-FC805E9A-2950-492A-AB74-7572A72950CCQ33851111-4E453565-2B09-4750-8B08-642C6E72D246Q33911230-03CFCB50-C828-4BCB-8711-304ABAE1C51FQ33989052-A03D1DAD-C312-449B-9E02-39AFDBA168C8Q34167708-733B2897-23A6-46CD-B628-E79A755FBB73Q34293299-E67966DA-D590-4E2B-A502-50B8680B48C4Q34425246-6593E811-875E-4A6A-94A8-56C478DEF01DQ34557856-36EB9740-3E09-4EEA-B9EE-46F5A71109F2Q35075394-CCE6BB93-D443-4C82-9ACE-CB73949D2D8AQ35164251-0B7792B5-BD40-46BA-8CD5-09C70A3955D2Q35673697-C78305DD-EBFE-4F9A-B58D-0E20CF7B310FQ35695499-7117DE2F-5C08-4DE9-9EB8-87D603CADAA3Q35804449-D05B1A71-8DB3-410B-A09D-78C41A3E553AQ35818531-E35D8954-9C49-4E2B-B9EA-9822C97F5072Q35839918-DE01DFE1-2B25-4249-B2C6-4BF8C6F1C042Q35853026-26AB5D7C-23D7-417C-B1E9-C82B1B2E2806Q35865441-EF98354C-B4F9-4A9A-9431-26B7CB6F6948Q35903385-DF28E546-6DAF-4BDD-A778-8B3563B80FF1Q35905629-1CD64FB1-D023-47E6-A61B-ECC1D1AAB271Q36276288-0AF31F65-95BF-421A-9BBE-E78F400A37E7Q36314597-4D038ACE-4210-464F-BA18-0EBA7BD2A00BQ36334327-FBADD1C4-AE30-469B-9D1D-F4F09AD126ECQ36384790-0A40827C-BC7C-4F2A-B658-E1FAD257422AQ36508955-B69CA122-D652-4582-AD37-5F3C5799F836Q36544358-D7AD4B33-A68A-4F80-863C-88BE8A227E48Q36686170-A651F097-EC0A-4158-BBCC-38C3E88D69A4Q36734942-AA5BAEAF-8045-48C5-969D-5AE6B5E45420Q36736892-64C13E0B-FD9A-47A8-ABFF-CADFED26E63FQ36769047-DA3ABDE8-096B-42E2-9C50-8170A0D32BEBQ37073666-F6F292A8-B619-446A-A41A-8E37DABC43F4Q37132625-261D86E5-ED10-4ACE-932B-CF06123233B5Q37178380-7F95B9E9-9ACF-4F98-BAF1-20EB155605B9Q37303829-8521AB55-4BC2-418E-BFBA-196B9640A799Q37322437-6814B28E-4CD8-41BB-AFFC-1F657A97100A
P2860
Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Identification of mcl-1 as a B ...... -1 antisense oligonucleotides.
@en
type
label
Identification of mcl-1 as a B ...... -1 antisense oligonucleotides.
@en
prefLabel
Identification of mcl-1 as a B ...... -1 antisense oligonucleotides.
@en
P2093
P1433
P1476
Identification of mcl-1 as a B ...... l-1 antisense oligonucleotides
@en
P2093
Brett P Monia
Cahit Akgul
Christian Sillaber
Edgar Selzer
Hans Skvara
Karl J Aichberger
Karoline Sonneck
Maria-Theresa Krauth
Matthias Mayerhofer
Sophia Derdak
P304
P356
10.1182/BLOOD-2004-02-0749
P407
P577
2004-12-30T00:00:00Z